David Hardison focuses on helping global life science organizations build capabilities to support evidence planning, generation, and management throughout the product life cycle. This includes leveraging his extensive international experience to develop strategies, tactics, and technologies for gaining optimal insights across proprietary research data, public data and Real World Data that help companies embrace Precision Medicine and Value-based Reimbursement. David came to Deloitte as a part of their acquisition of Recombinant Data Corporation where he served as Managing Director of Life Sciences. Recombinant was focused on optimizing the secondary use of health care data for use by life science companies and health care providers for research and development and value demonstration through better patient outcomes and affordable health economics. David is Past Chairman of the CDISC Board of Directors.
Exploiting AI: From Discovery to Treatment
11:10 AM - 12:00 PM